Structure of Repotrectinib
CAS No.: 1802220-02-5
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 5.3 nM, 1.01 nM, 1.26 nM and 1.08 nM for SRC, WT ALK, ALK G1202R and ALK L1196M, respectively.
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1802220-02-5 |
Formula : | C18H18FN5O2 |
M.W : | 355.37 |
SMILES Code : | O=C1NC[C@H](C)OC2=CC=C(F)C=C2[C@@H](C)NC3=NC4=C1C=NN4C=C3 |
MDL No. : | MFCD31544350 |
InChI Key : | FIKPXCOQUIZNHB-WDEREUQCSA-N |
Pubchem ID : | 135565923 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Target |
|
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
Ba/F3_G595R cells | 1 μM | 72 h | Ba/F3_G595R cells were sensitive to repotrectinib | PMC9277414 |
Ba/F3_WT cells | 1 μM | 72 h | Ba/F3_WT cells were sensitive to repotrectinib | PMC9277414 |
YU1079 | 0.097 μM | 72 h | To evaluate the anti-tumor activity of Repotrectinib in crizotinib-resistant ROS1 G2032R mutation models, results showed that Repotrectinib significantly inhibited the growth of YU1079 cells. | PMC10283448 |
YU1078 | 0.021 µM | 72 h | To evaluate the anti-tumor activity of Repotrectinib in treatment-naïve ROS1-rearranged NSCLC models, results showed that Repotrectinib significantly inhibited the growth of YU1078 cells. | PMC10283448 |
SK-N-BE | 510.8 ± 16.94 nM | 5 days | Repotrectinib has a weaker inhibitory effect on the proliferation of non-ALK-addicted neuroblastoma cells SK-N-BE. | PMC6920469 |
SK-N-AS | 594.8 ± 47.3 nM | 5 days | Repotrectinib has a weaker inhibitory effect on the proliferation of non-ALK-addicted neuroblastoma cells SK-N-AS. | PMC6920469 |
Kelly | 310.9 ± 7.9 nM | 5 days | Repotrectinib inhibits proliferation of ALK-addicted neuroblastoma cells and reduces phosphorylation levels of pY1604-ALK, pERK5, pSTAT3, p-p70 S6K, pAKT, and pERK. | PMC6920469 |
CLB-GE | 259.4 ± 6.3 nM | 5 days | Repotrectinib inhibits proliferation of ALK-addicted neuroblastoma cells and reduces phosphorylation levels of pY1604-ALK, pERK5, pSTAT3, p-p70 S6K, pAKT, and pERK. | PMC6920469 |
CLB-BAR | 124.1 ± 4.89 nM | 5 days | Repotrectinib inhibits proliferation of ALK-addicted neuroblastoma cells and reduces phosphorylation levels of pY1604-ALK, pERK5, pSTAT3, p-p70 S6K, pAKT, and pERK. | PMC6920469 |
M3B cells | 1 μM | 72 h | M3B cells were resistant to repotrectinib, IC50 of 295.7 nM | PMC9277414 |
KM12SM cells | 1 μM | 72 h | KM12SM cells were sensitive to repotrectinib, IC50 of 1.2 nM | PMC9277414 |
NIH-3T3-tv-a cells | 100 nM | 5 days | To evaluate the growth inhibitory effect of Repotrectinib on TPM3-NTRK1-G595R mutant spheroids, results showed that Repotrectinib significantly inhibited the growth of mutant spheroids. | PMC11572037 |
NIH-3T3-tv-a cells | 100 nM | 5 days | To evaluate the growth inhibitory effect of Repotrectinib on TPM3-NTRK1-F589L mutant spheroids, results showed that Repotrectinib significantly inhibited the growth of mutant spheroids. | PMC11572037 |
NIH-3T3-tv-a cells | 100 nM | 5 days | To evaluate the growth inhibitory effect of Repotrectinib on NTRK fusion-driven spheroids, results showed that Repotrectinib significantly inhibited the growth of spheroids. | PMC11572037 |
KM12 cells | <0.03 nM | 4 h | Repotrectinib was the most potent inhibitor of TRKA autophosphorylation, with an IC50 value less than 0.03 nM. | PMC9762329 |
Ba/F3 cells | <0.2 nM | 72 h | Repotrectinib showed the highest potency against wild-type TRKA, TRKB, and TRKC fusions, with IC50 values less than 0.2 nM. | PMC9762329 |
HCC78 ROS1L2026M | 1 - 5000 nM | 120 h | To evaluate the inhibitory effect of Repotrectinib on ROS1L2026M mutant cells, results showed significant resistance of ROS1L2026M cells to Repotrectinib | PMC10910754 |
HCC78 ROS1G2032R | 1 - 5000 nM | 120 h | To evaluate the inhibitory effect of Repotrectinib on ROS1G2032R mutant cells, results showed significant resistance of ROS1G2032R cells to Repotrectinib | PMC10910754 |
IRC and KM12 cells | 1-5000 nM | 72 hours | To assess the effect of Selpercatinib on the growth inhibition and TRK-mediated signaling in NTRK fusion-positive tumor cells. Results showed that Selpercatinib significantly inhibited tumor cell growth and TRK signaling. | PMC11300601 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Mice | YU1078 xenograft model | Oral | 15 mg/kg | Twice daily, for 21 days | To evaluate the anti-tumor activity of Repotrectinib in the YU1078 xenograft model, results showed that Repotrectinib significantly inhibited tumor growth and delayed tumor recurrence. | PMC10283448 |
Mice | Neuroblastoma xenograft model | Oral | 20 mg/kg, twice daily | Twice daily for 14 days | Repotrectinib significantly inhibits tumor growth in a neuroblastoma xenograft model, with a tumor growth inhibition (TGI) of 87.07%, and animals gained weight. | PMC6920469 |
Mice | NTRK fusion-driven glioma models | Intraperitoneal (i.p.) injection | 20 mg/kg | Twice a day for 25 hours | To evaluate the therapeutic effect of Repotrectinib on NTRK fusion-driven gliomas, results showed that Repotrectinib significantly reduced p-ERK and p-S6 levels in tumor tissue and induced apoptosis. | PMC11572037 |
Nude mice | NIH3T3 LMNA–TRKA xenograft model | Oral | 3 mg/kg, 10 mg/kg, 30 mg/kg | Twice daily, continuous treatment | Repotrectinib demonstrated significant antitumor activity in the LMNA–TRKAG595R xenograft model, achieving 95% tumor growth inhibition, 19% tumor regression, and 46% tumor regression at doses of 3 mg/kg, 10 mg/kg, and 30 mg/kg, respectively. | PMC9762329 |
SHO mice | Brain metastasis model | Oral | 15 mg/kg | Daily, continuous treatment | Single-agent repotrectinib treatment significantly inhibited tumor growth, and the combination with Gefitinib and Trametinib further prolonged mouse survival | PMC9277414 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT06352528 | Hepatic Impairment|Healthy Vol... More >>unteers Less << | PHASE1 | RECRUITING | 2025-07-24 | Local Institution - 0006, Miam... More >>i Lakes, Florida, 33014-2811, United States|Panax Clinical Research, Miami Lakes, Florida, 33014, United States|Local Institution - 0005, Orlando, Florida, 32809-3017, United States|Orlando Clinical Research Center, Orlando, Florida, 32809, United States|Local Institution - 0004, San Antonio, Texas, 78215, United States|Texas Liver Institute, San Antonio, Texas, 78215, United States Less << |
NCT06552234 | NSCLC Stage IV|NSCLC, Stage II... More >>I Less << | PHASE2 | RECRUITING | 1931-09-01 | CH Aix-en-Provence, Aix-en-Pro... More >>vence, Bouches Du Rh?ne, France|AP-HM, Marseille, Bouches Du Rh?ne, France|HIA Sainte Anne, Toulon, Var, France|CHU Angers, Angers, France|CHU Bordeaux, Bordeaux, France|CHU Brest, Brest, France|Centre Fran?ois Baclesse, Caen, France|CH Chambéry, Chambéry, France|H?pitaux civils de Colmar, Colmar, France|CHI Créteil, Créteil, France|CHD Vendée, La Roche-sur-Yon, France|CHRU Lille, Lille, France|CHU Limoges, Limoges, France|Hospices Civils de Lyon, Lyon, France|CH Cornouaille, Quimper, France|CHU Rennes, Rennes, France|CHU Rouen, Rouen, France|H?pital Foch, Suresnes, France|CHU Toulouse, Toulouse, France|H?pitaux Nord-Ouest, Villefranche-sur-Sa?ne, France Less << |
NCT05926232 | - | AVAILABLE | - | - | |
NCT06315010 | NSCLC|Brain Metastases|ROS1 Ge... More >>ne Rearrangement Less << | PHASE2 | NOT_YET_RECRUITING | 2025-04-28 | - |
Tags: Repotrectinib | TPX-0005 | TPX0005 | TPX 0005 | ROS Kinase | Trk Receptor | ROS1 inhibitor | NTRK inhibitor | Neurotrophic Tyrosine Receptor Kinase | Fusion-Positive Cancer | TRK inhibitor | ALK inhibitor | Tyrosine Receptor Kinase | Anaplastic lymphoma kinase | ALK tyrosine kinase receptor | 1802220-02-5
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL